Results for tag: "Cardiac Amyloidosis Drugs"

The cardiac amyloidosis drugs market is a specialized sector within the broader category of cardiovascular drugs focused on developing treatments for cardiac amyloidosis, a condition characterized by the accumulation of amyloid proteins in the heart tissue. This accumulation leads to stiffening of the heart walls that impairs its function and can cause heart failure and other cardiac complications. The disease can be a result of various types of amyloidosis, including AL amyloidosis associated with plasma cell disorders and ATTR amyloidosis which can be hereditary or acquired with age. In contrast to general cardiovascular medications that often target a wide range of heart conditions such as hypertension, arrhythmias, or hyperlipidemia, cardiac amyloidosis therapies are more targeted. They aim to reduce the production of amyloid proteins, stabilize the existing amyloid fibrils to prevent further deposition, or support the clearance of amyloid deposits in cardiac tissue. Given the rarity and complexity of cardiac amyloidosis, therapeutic development encompasses novel drug candidates, including small molecules, monoclonal antibodies, and RNA-targeted therapies. Several companies in the cardiac amyloidosis drugs market are active contributors to the field of rare cardiac conditions. Among them, Pfizer Inc., Alnylam Pharmaceuticals, and Ionis Pharmaceuticals are notable for their efforts in advancing treatments. These firms are engaged in research and development of drugs that aim to improve clinical outcomes for patients with various forms of cardiac amyloidosis. Their work contributes to a growing body of treatments that address this challenging and previously Show Less Read more